| Key takeaway: Amivantamab combined with lazertinib significantly improved PFSl compared to osimertinib in treatment-naïve patients with EGFR-mutant advanced non-small cell lung cancer, including those with high-risk features, establishing it as a promising new standard of care.
Amivantamab (ami), an EGFR-MET bispecific antibody with immune cell-directing activity, combined with lazertinib (laz), a CNS-penetrant third-generation EGFR TKI, significantly improved median progression-free survival (mPFS) compared to osimertinib (osi) in treatment-naïve patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) in the MARIPOSA trial. This benefit extended to high-risk subgroups, including patients with TP53 co-mutations, detectable circulating tumor DNA (ctDNA) at baseline, and those with baseline brain or liver metastases. Ami+laz showed superiority over osi in mPFS across these subgroups, underscoring its potential as a new standard of care in this patient population. Read more. |
